Mirum Pharmaceuticals, Inc.
MIRM
Classificação em ações
#3229
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Preço da ação
$85.25
Valor de mercado
$5.54B
Variação (1 dia)
3.66%
Variação (1 ano)
16.73%
País
US
Negociar Mirum Pharmaceuticals, Inc. (MIRM)
Categoria
Healthcare
Rácio P/S de Mirum Pharmaceuticals, Inc. (MIRM)
Rácio P/S em October 2026 TTM: 8.40
De acordo com os relatórios financeiros mais recentes e o preço das ações da Mirum Pharmaceuticals, Inc., o rácio P/S atual (TTM) é 8.40. No final de 2023, o rácio P/S era 6.48.
Histórico do rácio P/S da Mirum Pharmaceuticals, Inc. de 2018 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 8.40 | 44.09% |
| 2024 | 5.83 | -9.93% |
| 2023 | 6.48 | -24.37% |
| 2022 | 8.56 | -66.12% |
| 2021 | 25.27 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | 19.31% |
US
|
|
| 40.55 | 382.73% |
US
|
|
| 3.96 | -52.85% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 20.78% |
NL
|
